X4 PHARMACEUTICALS, INC Derivative Liability, Fair Value, Gross Liability
X4 PHARMACEUTICALS, INC (XFOR) had Derivative Liability, Fair Value, Gross Liability of $288.00 thousand as of 2021-03-31, per its 10-K filed 2022-03-17.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2022-03-17
- 2021-03-31: Derivative Liability, Fair Value, Gross Liability $288.00K.
- 2020-03-31: Derivative Liability, Fair Value, Gross Liability $288.00K.
- 2019-06-30: Derivative Liability, Fair Value, Gross Liability $0.00.
- 2019-03-31: Derivative Liability, Fair Value, Gross Liability $288.00K; Derivative Liability, Fair Value, Gross Liability as first filed $0.00.
| Period end | Derivative Liability, Fair Value, Gross Liability | Derivative Liability, Fair Value, Gross Liability as first filed |
|---|---|---|
| 2021-03-31 | $288.00K 10-K · filed 2022-03-17 | |
| 2020-03-31 | $288.00K 10-K · filed 2021-03-19 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $288.00K 10-K · filed 2020-03-12 | $0.00 10-Q · filed 2019-05-15 |
| 2019-03-13 | $5.20M 10-K · filed 2022-03-17 | $5.24M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |